

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI777109

| | | |
|---|--|-----------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT | |
| NATURE OF CONVEYANCE: | Intellectual Property Security Agreement | |
| CONVEYING PARTY DATA | | |
| Name | | Execution Date |
| VIRACTA SUBSIDIARY, INC. | | 01/23/2025 |
| RECEIVING PARTY DATA | | |
| Company Name: | Oxford Finance LLC, as Collateral Agent | |
| Street Address: | 115 South Union St, Suite 300 | |
| City: | Alexandria | |
| State/Country: | VIRGINIA | |
| Postal Code: | 22314 | |
| PROPERTY NUMBERS Total: 12 | | |
| Property Type | Number | |
| Patent Number: | 10857152 | |
| Patent Number: | 12083119 | |
| Patent Number: | 10953011 | |
| Application Number: | 17613718 | |
| Application Number: | 17766643 | |
| Application Number: | 18080570 | |
| Application Number: | 18580500 | |
| Application Number: | 63638252 | |
| Application Number: | 18034296 | |
| Application Number: | 18364074 | |
| Patent Number: | 11918237 | |
| Patent Number: | 7932246 | |
| CORRESPONDENCE DATA | | |
| Fax Number: | | |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | | |
| Phone: | 2025218721 | |
| Email: | ipteam@cogencyglobal.com | |
| Correspondent Name: | Troy Jones | |
| Address Line 1: | 1025 Connecticut Ave NW, Suite 712 | |
| Address Line 4: | Washington, DISTRICT OF COLUMBIA 20036 | |

PATENT

| | |
|---|--------------|
| ATTORNEY DOCKET NUMBER: | 2631174 TJ |
| NAME OF SUBMITTER: | Troy Jones |
| SIGNATURE: | /Troy Jones/ |
| DATE SIGNED: | 01/23/2025 |
| Total Attachments: 7 source=EXECUTED.Oxford-SVB - Viracta - IP Security Agreement (Subsidiary) (01.2025)#page1.tiff source=EXECUTED.Oxford-SVB - Viracta - IP Security Agreement (Subsidiary) (01.2025)#page2.tiff source=EXECUTED.Oxford-SVB - Viracta - IP Security Agreement (Subsidiary) (01.2025)#page3.tiff source=EXECUTED.Oxford-SVB - Viracta - IP Security Agreement (Subsidiary) (01.2025)#page4.tiff source=EXECUTED.Oxford-SVB - Viracta - IP Security Agreement (Subsidiary) (01.2025)#page5.tiff source=EXECUTED.Oxford-SVB - Viracta - IP Security Agreement (Subsidiary) (01.2025)#page6.tiff source=EXECUTED.Oxford-SVB - Viracta - IP Security Agreement (Subsidiary) (01.2025)#page7.tiff | |

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of January 23, 2025 by and between OXFORD FINANCE LLC, a Delaware limited liability company, as collateral agent for the Lenders (the “**Lenders**”) described in the Loan Agreement (in such capacity, the “**Collateral Agent**”), and VIRACTA SUBSIDIARY, INC., a Delaware corporation (“**Grantor**”).

RECITALS

A. Lenders have made certain advances of money and extended certain financial accommodations to Grantor (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement dated as of November 4, 2021, as amended by that certain First Amendment to Loan and Security Agreement dated as of August 26, 2022, that certain Second Amendment to Loan and Security Agreement dated as of March 1, 2024, and as amended by that certain Third Amendment to Loan and Security Agreement dated as of the date hereof (the “**Third Amendment**”) (as may be further amended, supplemented or otherwise modified from time to time, the “**Loan Agreement**”; capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to enter into the Third Amendment, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Loan Agreement, Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

VIRACTA SUBSIDIARY, INC.

VIRACTA THERAPEUTICS, INC.
2533 S. Coast Highway 101, Suite 210
Cardiff by the Sea, CA 92007
Attn: Chief Executive Officer
Fax: (858) 771-4188
Email: legal@viracta.com

Signed by:
By: Mark Rothera
Name: Mark Rothera
Title: President and Chief Executive Officer

COLLATERAL AGENT:

Address of Collateral Agent:

OXFORD FINANCE LLC

OXFORD FINANCE LLC
115 South Union Street
Suite 300
Alexandria, VA 22314
Attention: Legal Department
Fax: (703) 519-5225
Email: LegalDepartment@oxfordfinance.com

By: _____
Name: Colette H. Featherly
Title: Senior Vice President

[Signature Page to Intellectual Property Security Agreement (Third Am.)]

PATENT
REEL: 070000 FRAME: 0004

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

VIRACTA SUBSIDIARY, INC.

VIRACTA THERAPEUTICS, INC.
2533 S. Coast Highway 101, Suite 210
Cardiff by the Sea, CA 92007
Attn: Chief Executive Officer
Fax: (858) 771-4188
Email: legal@viracta.com

By: _____
Name: Mark Rothera
Title: President and Chief Executive Officer

Address of Collateral Agent:

OXFORD FINANCE LLC
115 South Union Street
Suite 300
Alexandria, VA 22314
Attention: Legal Department
Fax: (703) 519-5225
Email: LegalDepartment@oxfordfinance.com

COLLATERAL AGENT:

OXFORD FINANCE LLC

By: _____
Name: Colette H. Featherly
Title: Senior Vice President

[Signature Page to Intellectual Property Security Agreement (Third Am.)]

PATENT
REEL: 070000 FRAME: 0005

EXHIBIT A

Copyrights

NONE

| <u>Description</u> | <u>Registration Number</u> | <u>Registration Date</u> |
|---------------------------|-----------------------------------|---------------------------------|
| | | |
| | | |
| | | |
| | | |

EXHIBIT B**Patents**

| Country | Application Number | Patent Number | Issue Date | Title |
|---------|--------------------|------------------|-------------|--|
| US | 15/959,482 | 10,857,152 | 08-Dec-2020 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS |
| US | 17/545,217 | 12,083,119 | 10-Sep-2024 | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS |
| US | 18/796,094 | | | METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS |
| US | 18/057,161 | | | HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY |
| EP | 17828555.7 | | | HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY |
| CN | 201780056835.0 | | | HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY |
| JP | 2019-522627 | 7373991 | 26-Oct-2023 | HISTONE DEACETYLASE INHIBITORS FOR USE IN IMMUNOTHERAPY |
| HK | 19131046.5 | | | HISTONE DEACETYLASE INHIBITORS |
| BR | P10611522-5 | P10611522-5 | 03-Aug-2021 | HISTONE DEACETYLASE INHIBITORS |
| CA | 2605050 | 2605050 | 21-Jan-2014 | HISTONE DEACETYLASE INHIBITORS |
| CN | 200680013647.1 | ZL200680013647.1 | 14-Sep-2011 | HISTONE DEACETYLASE INHIBITORS |
| IL | 186362 | IL186362 | 31-Jan-2012 | HISTONE DEACETYLASE INHIBITORS |
| JP | 2008-511780 | 4954200 | 23-Mar-2012 | HISTONE DEACETYLASE INHIBITORS |
| MX | MX/a/2007/013066 | 268717 | 28-Jul-2009 | HISTONE DEACETYLASE INHIBITORS |
| NZ | 562519 | 562519 | 08-Mar-2011 | HISTONE DEACETYLASE INHIBITORS |
| US | 11/918,237 | 7,932,246 | 26-Apr-2011 | HISTONE DEACETYLASE INHIBITORS |
| EP | 17828565.6 | | | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES |
| GB | 1901327.5 | 2567362 | 20-Apr-2022 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES |
| CN | 201780056873.6 | | | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES |
| JP | 2019-522629 | 7158104 | 13-Oct-2022 | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES |
| US | 16/317,766 | | | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES |
| HK | 19131057.2 | | | HDAC INHIBITORS FOR USE WITH NK CELL BASED THERAPIES |
| US | 16/924,082 | 10,953,011 | 23-Mar-2021 | METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS |
| EP | 20814826.2 | | | METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS |
| CN | 202080055863.2 | | | METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS |

| Country | Application Number | Patent Number | Issue Date | Title |
|---------|--------------------|---------------|-------------|--|
| JP | 2021-570435 | | | METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS |
| KR | 10-2021-7042700 | | | METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS |
| MX | MX/a/2021/014639 | | | METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS |
| RU | 2021138004 | 2819782 | 24-May-2024 | METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS |
| US | 17/613,718 | | | METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS |
| TW | 109117909 | 1853940 | 01-Sep-2024 | METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS |
| HK | 62022059595.8 | | | METHODS OF TREATING VIRALLY ASSOCIATED CANCERS WITH HISTONE DEACETYLASE INHIBITORS |
| US | 17/766,643 | | | DOSAGES FOR HDAC TREATMENT WITH REDUCED SIDE EFFECTS |
| US | 18/080,570 | 11,760,748 | 19-Sep-2023 | HDAC INHIBITOR SOLID STATE FORMS |
| US | 18/364,074 | 12,012,396 | 18-Jun-2024 | HDAC INHIBITOR SOLID STATE FORMS |
| EP | 21887546.6 | | | HDAC INHIBITOR SOLID STATE FORMS |
| CN | 202180088245.2 | | | HDAC INHIBITOR SOLID STATE FORMS |
| JP | 2023-525959 | | | HDAC INHIBITOR SOLID STATE FORMS |
| US | 18/034,296 | | | HDAC INHIBITOR SOLID STATE FORMS |
| TW | 110140165 | | | HDAC INHIBITOR SOLID STATE FORMS |
| HK | 62023083931.3 | | | HDAC INHIBITOR SOLID STATE FORMS |
| EP | 22846572.0 | | | CANCER TREATMENT COMBINATIONS |
| CN | 202280063761.4 | | | CANCER TREATMENT COMBINATIONS |
| JP | 2024-502433 | | | CANCER TREATMENT COMBINATIONS |
| US | 18/580,500 | | | CANCER TREATMENT COMBINATIONS |
| WO | PCT/US2023/077256 | | | DOSING METHODS FOR HDAC INHIBITOR COMPOUNDS |
| US | 63/638,252 | | | HDAC INHIBITOR FORMULATIONS |

EXHIBIT C

Trademarks

NONE

| <u>Country</u> | <u>Mark Description</u> | <u>Serial/Registration No.</u> | <u>File Date</u> |
|-----------------------|--------------------------------|---------------------------------------|-------------------------|
| | | | |
| | | | |
| | | | |
| | | | |